Maxcyte (MXCT) Gross Margin (2020 - 2025)
Historic Gross Margin for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to 76.63%.
- Maxcyte's Gross Margin rose 2400.0% to 76.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.97%, marking a year-over-year decrease of 60100.0%. This contributed to the annual value of 81.62% for FY2024, which is 69000.0% down from last year.
- Per Maxcyte's latest filing, its Gross Margin stood at 76.63% for Q3 2025, which was up 2400.0% from 82.14% recorded in Q2 2025.
- In the past 5 years, Maxcyte's Gross Margin ranged from a high of 90.83% in Q1 2022 and a low of 73.76% during Q4 2024
- Its 5-year average for Gross Margin is 85.88%, with a median of 87.63% in 2024.
- In the last 5 years, Maxcyte's Gross Margin surged by 29500bps in 2023 and then tumbled by -162000bps in 2024.
- Over the past 5 years, Maxcyte's Gross Margin (Quarter) stood at 87.92% in 2021, then decreased by 0bps to 87.55% in 2022, then grew by 3bps to 89.96% in 2023, then fell by -18bps to 73.76% in 2024, then rose by 4bps to 76.63% in 2025.
- Its Gross Margin stands at 76.63% for Q3 2025, versus 82.14% for Q2 2025 and 85.59% for Q1 2025.